In the wake of the RACE Act, identifying and partnering with key stakeholders, namely patient organizations and academia, will enable companies to efficiently overcome key barriers.
This whitepaper offers a high-level orientation around the key barriers to readiness and critical success factors for companies navigating the pediatric oncology space. The primary focus of this whitepaper is on how collaboration with patient organizations will be critical to overcoming the obstacles most companies will encounter.
Together, the elements of this whitepaper aim to support collaboration between industry and patient organizations as a valuable strategy to ensuing readiness for the RACE Act.
Medicines for Children: What Parents Need to Know
COVID-19 Prevents Children from Receiving Important Vaccinations
Measles is a highly contagious disease that often affects children, and may be fatal. Harris Dalrymple, PRA’s Executive Director of Scientific…